# Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

> **NCT01294384** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 305 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** carboxymethylcellulose sodium based New Eye Drop Formulation 1
- **DRUG:** carboxymethylcellulose sodium based New Eye Drop Formulation 2
- **DRUG:** carboxymethylcellulose sodium based Eye Drops

## Key facts

- **NCT ID:** NCT01294384
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-01
- **Primary completion:** 2012-09-25
- **Final completion:** 2012-09-25
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294384, "Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01294384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*